<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cholestyramine: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cholestyramine: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Cholestyramine: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9258" href="/d/html/9258.html" rel="external">see "Cholestyramine: Drug information"</a> and <a class="drug drug_patient" data-topicid="10839" href="/d/html/10839.html" rel="external">see "Cholestyramine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F150870"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Prevalite;</li>
<li>Questran;</li>
<li>Questran Light</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866318"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Cholestyramine-ODAN;</li>
<li>DOM-Cholestyramine;</li>
<li>JAMP-Cholestyramine Sugar Free;</li>
<li>Olestyr;</li>
<li>Olestyr Light</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1051702"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antilipemic Agent, Bile Acid Sequestrant</span></li></ul></div>
<div class="block don drugH1Div" id="F53462407"><span class="drugH1">Dosing: Neonatal</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d9d54a05-e613-4c67-b603-2a3a36b6400d">Diaper dermatitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diaper dermatitis:</b> Limited data available: Topical: Apply to affected area with each diaper change. <b>Note:</b> Product not commercially available; may be prepared as an extemporaneously compounded ointment or paste in Aquaphor; usual concentration: 5% to 10%, although higher concentrations (up to 20%) have been compounded; some centers have also used petrolatum as the base for compounding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-White.2','lexi-content-ref-Williams.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-White.2','lexi-content-ref-Williams.1'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F150884"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d9d54a05-e613-4c67-b603-2a3a36b6400d">Diaper dermatitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diaper dermatitis:</b> Limited data available: Topical: Infants and Children: Apply to affected area with each diaper change. <b>Note:</b> Product not commercially available; may be prepared as an extemporaneously compounded ointment or paste in Aquaphor or polyethylene glycol; usual concentration 5% to 10%, although higher concentrations (up to 20%) have been compounded; some centers have also used petrolatum as the base for compounding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Preckshot.1','lexi-content-ref-White.2','lexi-content-ref-Williams.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Preckshot.1','lexi-content-ref-White.2','lexi-content-ref-Williams.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="560908d5-ebc4-44c2-80e2-fb9e5eb5b6b8">Hyperlipidemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperlipidemia:</b> Limited data available: <b>Note</b>
<b>:</b> Begin treatment after an adequate trial (6 to 12 months) of intensive lifestyle modification emphasizing body weight normalization and diet. Should not be used in pediatric patients with hypertriglyceridemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28437620']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28437620'])">Ref</a></span>). Dosages are expressed in terms of anhydrous resin:</p>
<p style="text-indent:-2em;margin-left:4em;">Age-directed (fixed-dosing): Children ≥6 years and Adolescents: Oral: Initial: 2 to 4 g/day for 1 week, then increase as tolerated to 8 g/day; children &lt;10 years of age may only tolerate daily dose of 4 g (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17377073','lexi-content-ref-8757557','lexi-content-ref-8757561']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17377073','lexi-content-ref-8757557','lexi-content-ref-8757561'])">Ref</a></span>); lipid-lowering effects are better if dose is administered as a single daily dose with the evening meal (single daily morning doses are less effective); however, for patients unable to tolerate doses administered as a single dose, total daily doses may be divided into 2 or 3 divided doses with meals (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Daniels.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Daniels.1'])">Ref</a></span>); doses &gt;8 g/day may not provide additional significant cholesterol-lowering effects, but may increase adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8757557']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8757557'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Weight-directed dosing: Children and Adolescents: Oral: 240 mg/kg/day in 3 divided doses; titrate to effect, maximum daily dose: 8 g/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gal.2007']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gal.2007'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0437d64a-6e4d-4b96-8f99-82c938b34d8f">Pruritus secondary to cholestasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pruritus secondary to cholestasis:</b> Limited data available: <b>Note:</b> Dosages are expressed in terms of anhydrous resin:</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≤10 years: Oral: 240 mg/kg/day in 2 or 3 divided doses administered in the morning around breakfast and if necessary, the third dose at lunch (see "Administration: Pediatric"); may titrate dose to effect. Some experts have suggested a maximum daily dose of 4 g/<b>day</b>; however, higher doses have been reported to treat pruritus in pediatric patients &lt;10 years; in a case report (age: 9 years), the reported effective dose range was 3.3 to 6.6 g/day; in another case series (n=3; ages: 3 to 9 years), the reported range was 1.7 to 10 g/day; in some patients, higher doses were associated with increased steatorrhea and required dosage reduction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17519457','lexi-content-ref-8757557']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17519457','lexi-content-ref-8757557'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children &gt;10 years and Adolescents: Oral: 240 mg/kg/day administered in the morning before breakfast; may titrate dose to effect. Some experts have suggested a maximum daily dose of 8 g/<b>day</b>; in adult patients, the AASLD guidelines recommend an initial dose of 4 g/day; may titrate up to 16 g/day; in some patients, higher doses have been associated with increased steatorrhea requiring dose reduction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17519457','lexi-content-ref-22413872','lexi-content-ref-19554543','lexi-content-ref-8757557']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17519457','lexi-content-ref-22413872','lexi-content-ref-19554543','lexi-content-ref-8757557'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e8156741-220d-4781-a3c6-703c0d364d85">Diarrhea secondary to intestinal failure, short-bowel syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diarrhea secondary to intestinal failure, short-bowel syndrome:</b> Very limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Corkins.1','lexi-content-ref-Kliegman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Corkins.1','lexi-content-ref-Kliegman.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: Oral: 240 mg/kg/day in 2 to 3 divided doses; maximum daily dose: 8 g/<b>day</b> has been suggested (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18042954','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18042954','lexi-content-ref-Manu.1'])">Ref</a></span>); however, robust clinical trials have not been completed in pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Corkins.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Corkins.1'])">Ref</a></span>). <b>Note:</b> Therapeutic effect may differ among products due to excipients (eg, sorbitol, sucrose) which could potentially worsen diarrhea.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51084760"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling; however, use with caution in renal impairment; may cause hyperchloremic acidosis.</p></div>
<div class="block dohp drugH1Div" id="F51084761"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary; not absorbed from the gastrointestinal tract.</p></div>
<div class="block doa drugH1Div" id="F150873"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9258" href="/d/html/9258.html" rel="external">see "Cholestyramine: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dosages are expressed in terms of anhydrous resin.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8cb7fa40-b34d-4623-94b1-fefd274e6b46">Chronic diarrhea due to bile acid malabsorption</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic diarrhea due to bile acid malabsorption (off-label use): Oral:</b> Initial: 2 to 4 g/day as a single dose or in divided doses; increase gradually (eg, by 4 g at weekly intervals) based on response and tolerability; daily doses may be administered in 1 to 4 divided doses; maximum: 24 g/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32010878','lexi-content-ref-24602022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32010878','lexi-content-ref-24602022'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f71eb8fe-d05e-4ef8-91ed-8e7a986cef46">Dyslipidemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dyslipidemia:</b>
<b>Oral:</b> Initial: 4 g 1 to 2 times/day; increase gradually over ≥1-month intervals; maintenance: 8 to 16 g/day divided in 2 doses; maximum: 24 g/day. <b>Note:</b> May be considered in patients with fasting triglyceride level ≤300 mg/dL who do not meet cholesterol treatment goals with dietary modification and other lipid-lowering therapies (eg, maximally tolerated statin and ezetimibe) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="28b7e977-bc42-4ad5-93cc-e3cebb07835e">Enhanced elimination of leflunomide</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Enhanced elimination of leflunomide (off-label use):</b>
<b>Oral:</b> 4 g every 6 hours for 2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30926241']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30926241'])">Ref</a></span>) <b>or</b> 8 g 3 times daily for 11 days (Arava prescribing information 2016<i>)</i>. <b>Note: </b>In patients who do <b>not </b>require rapid elimination, days of administration may be nonconsecutive (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26633044']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26633044'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="635b4491-18d8-4a22-94bc-de8c22e8f36c">Hyperthyroidism associated with Graves disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperthyroidism associated with Graves disease (adjunctive therapy) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> May be used as an adjunct to standard therapies in patients where euthyroidism cannot be achieved prior to thyroidectomy, there is an urgent need for thyroidectomy, or with allergies to antithyroid drugs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27521067']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27521067'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 4 g 2 to 4 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8784067','lexi-content-ref-8435884','lexi-content-ref-15853819']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8784067','lexi-content-ref-8435884','lexi-content-ref-15853819'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0e25139f-e3be-465b-8c29-0ad101a43641">Pruritus associated with cholestasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pruritus associated with cholestasis: Oral: </b>Initial: 4 g once or twice daily; may increase dose gradually up to 16 g/day in 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30070375','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30070375','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f1475225-321a-4979-8339-62b5dcdf93d0">Thyroid storm</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thyroid storm (adjunctive agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>May use in combination with other appropriate agents in patients with severe or refractory disease, particularly in patients who cannot take antithyroid drugs (eg, propylthiouracil) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17127140','lexi-content-ref-Ross.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17127140','lexi-content-ref-Ross.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>4 g four times/day until thyroid storm resolves (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17127140']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17127140'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50992000"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>Patients with kidney impairment (eg, eGFR &lt;60 mL/minute/1.73 m<sup>2</sup>) may be at increased risk of hyperchloremic metabolic acidosis, especially when combined with other precipitating factors (eg, volume depletion, higher cholestyramine doses). Monitor electrolytes and anion gap frequently in patients at high risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-717343','lexi-content-ref-3861176','lexi-content-ref-6597713','lexi-content-ref-26425378','lexi-content-ref-8879322','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-717343','lexi-content-ref-3861176','lexi-content-ref-6597713','lexi-content-ref-26425378','lexi-content-ref-8879322','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> No dosage adjustment necessary for any degree of kidney dysfunction (no systemic absorption) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be significantly dialyzed: No supplemental dose or dosage adjustment necessary (no systemic absorption) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be significantly dialyzed: No dosage adjustment necessary (no systemic absorption) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50989241"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary; not absorbed from the gastrointestinal tract.</p></div>
<div class="block arsc drugH1Div" id="F58074206"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Constipation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Constipation</b> is the most common adverse effect associated with cholestyramine therapy; most cases of constipation are mild, transient, and self-limiting. Constipation may lead to or exacerbate preexisting hemorrhoids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4746523']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4746523'])">Ref</a></span>). Patients experiencing constipation may require dosage adjustment or discontinuation of therapy; adequate water and fiber intake or the addition of a stool softener may mitigate this effect. While no direct comparisons have been conducted regarding the risk of constipation between bile acid sequestrants, the incidence of constipation reported in clinical trials is relatively higher with cholestyramine as compared to colesevelam (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16616026','lexi-content-ref-6361299']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16616026','lexi-content-ref-6361299'])">Ref</a></span>). <b>Gastrointestinal obstruction</b> has also been reported in pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-850604','lexi-content-ref-6767374','lexi-content-ref-8757561']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-850604','lexi-content-ref-6767374','lexi-content-ref-8757561'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; cholestyramine is a bile acid sequestrant that forms a nonabsorbable complex with bile acids in the intestine. In turn, the water content in the stool is reduced leading to constipation. <i></i></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; may persist for years with continued cholestyramine therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6361299']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6361299'])">Ref</a></span>). <i></i></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>
<i>:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Patients &gt;60 years of age</p>
<p style="text-indent:-2em;margin-left:6em;">• High dose</p>
<p style="text-indent:-2em;margin-left:6em;">• Rapid dose titration</p>
<p style="text-indent:-2em;margin-left:6em;">• Decreased gastrointestinal motility (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17368279']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17368279'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Recent abdominal surgery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17368279','lexi-content-ref-8757561']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17368279','lexi-content-ref-8757561'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior history of gastrointestinal obstruction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17368279']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17368279'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Fat-soluble vitamin/folate deficiency</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Administration of bile acid sequestrants, including cholestyramine, may cause reversible fat-soluble vitamin and/or folate deficiencies in adult and pediatric patients resulting in various clinical issues (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8757561','lexi-content-ref-1168607']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8757561','lexi-content-ref-1168607'])">Ref</a></span>). Night blindness secondary to <b>vitamin A deficiency</b>, osteomalacia due to <b>vitamin D deficiency</b>, and bleeding secondary to <b>vitamin K deficiency</b> have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-640344','lexi-content-ref-5410402','lexi-content-ref-5020877','lexi-content-ref-3948073','lexi-content-ref-13781611','lexi-content-ref-12688565']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-640344','lexi-content-ref-5410402','lexi-content-ref-5020877','lexi-content-ref-3948073','lexi-content-ref-13781611','lexi-content-ref-12688565'])">Ref</a></span>). Fetal vitamin K deficiency resulting in a fatal subdural hematoma secondary to maternal vitamin K deficiency has also been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7756215']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7756215'])">Ref</a></span>). Vitamin supplementation or treatment discontinuation may be required.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Dose-related; the binding of cholestyramine to bile acids interferes with fat absorption; consequently, malabsorption of fat-soluble vitamins and folate may result in deficiencies.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; a wide range of onset (ie, days to years) has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3948073','lexi-content-ref-8757561','lexi-content-ref-12688565','lexi-content-ref-1168607']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3948073','lexi-content-ref-8757561','lexi-content-ref-12688565','lexi-content-ref-1168607'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>
<i>:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Chronic use</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hemorrhage</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">The use of cholestyramine has been associated with <b>hemorrhage</b> in adult and pediatric patients; bleeding complications have included epistaxis, bruising, genitourinary bleeding, gastrointestinal bleeding, and periarticular bleeding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24921636','lexi-content-ref-27482192','lexi-content-ref-5410402','lexi-content-ref-3948073','lexi-content-ref-13781611','lexi-content-ref-12688565']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24921636','lexi-content-ref-27482192','lexi-content-ref-5410402','lexi-content-ref-3948073','lexi-content-ref-13781611','lexi-content-ref-12688565'])">Ref</a></span>). Hemorrhage is reversible upon discontinuation; however, recurrence has been reported following reinitiation of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27482192','lexi-content-ref-5410402','lexi-content-ref-3948073','lexi-content-ref-12688565']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27482192','lexi-content-ref-5410402','lexi-content-ref-3948073','lexi-content-ref-12688565'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> There are multiple mechanisms by which cholestyramine therapy may result in hemorrhage. Malabsorption of fat-soluble vitamins, including vitamin K, may occur with cholestyramine use; the subsequent hypoprothrombinemia associated with vitamin K deficiency may lead to hemorrhage and bleeding complications. In addition, crystal formation and deposition secondary to the use of ion exchange resins (eg, cholestyramine) may result in mucosal damage and bleeding complications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24921636','lexi-content-ref-27482192']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24921636','lexi-content-ref-27482192'])">Ref</a></span>). <i></i></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; a wide range of onset (ie, days to years) has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3948073','lexi-content-ref-12688565']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3948073','lexi-content-ref-12688565'])">Ref</a></span>). <i></i></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>
<i>:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Chronic use</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hyperchloremic metabolic acidosis</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Use of cholestyramine may result in reversible <b>hyperchloremic metabolic acidosis</b> in adult and pediatric patients, especially in the presence of precipitating conditions (eg, kidney impairment, volume depletion, concomitant administration of aldosterone antagonists) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-717343','lexi-content-ref-3861176','lexi-content-ref-6597713','lexi-content-ref-26425378','lexi-content-ref-4817847','lexi-content-ref-1634640']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-717343','lexi-content-ref-3861176','lexi-content-ref-6597713','lexi-content-ref-26425378','lexi-content-ref-4817847','lexi-content-ref-1634640'])">Ref</a></span>). Hyperchloremic acidosis may be severe, requiring discontinuation of cholestyramine therapy and initiation of appropriate treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-717343','lexi-content-ref-3861176','lexi-content-ref-6597713','lexi-content-ref-26425378','lexi-content-ref-4817847','lexi-content-ref-1634640']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-717343','lexi-content-ref-3861176','lexi-content-ref-6597713','lexi-content-ref-26425378','lexi-content-ref-4817847','lexi-content-ref-1634640'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Dose-related; cholestyramine is an anion exchange resin that binds bile acids by swapping chloride anions. This exchange results in a loss of bicarbonate ions and an accumulation of chloride ions. Generally, the kidneys compensate for these changes; however, when the compensatory mechanisms are inhibited by urinary acidification (eg, due to kidney impairment, volume depletion, concomitant administration of aldosterone antagonists), hyperchloremic metabolic acidosis becomes apparent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26425378']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26425378'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; timing of onset may be dependent on the presence of precipitating conditions (eg, kidney impairment, volume depletion, initiation of therapy with an aldosterone antagonist [eg, spironolactone]). Onset may be rapid in the presence of precipitating factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26425378','lexi-content-ref-4817847']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26425378','lexi-content-ref-4817847'])">Ref</a></span>). <i></i></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>
<i>:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26425378']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26425378'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Volume depletion (eg, secondary to diarrhea or infection) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26425378']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26425378'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant administration of an aldosterone antagonist (eg, spironolactone) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26425378','lexi-content-ref-1634640']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26425378','lexi-content-ref-1634640'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Younger or smaller patients whose relative dose may be higher as compared to older or larger patients <i></i></p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypertriglyceridemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Bile acid sequestrants, including cholestyramine, may result in reversible <b>hypertriglyceridemia</b>, especially in patients with elevated baseline fasting triglyceride concentrations or type III hyperlipoproteinemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774','lexi-content-ref-28487440','lexi-content-ref-24239923']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774','lexi-content-ref-28487440','lexi-content-ref-24239923'])">Ref</a></span>). Treatment should <b>not</b> be initiated when baseline fasting triglyceride concentrations are ≥300 mg/dL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36031461']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36031461'])">Ref</a></span>); cautious use with appropriate monitoring is recommended if baseline fasting triglyceride concentration is between 250 and 299 mg/dL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24239923']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24239923'])">Ref</a></span>). Discontinuation of therapy is warranted with severely elevated triglycerides (ie, serum triglycerides &gt;400 mg/dL [(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24239923']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24239923'])">Ref</a></span>)] or if signs and symptoms of acute pancreatitis occur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36031461']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36031461'])">Ref</a></span>); hypertriglyceridemia may persist with continued administration of cholestyramine.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6361299']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6361299'])">Ref</a></span>). Bile acids in the gastrointestinal tract activate the farnesoid X receptor (FXR), which subsequently increases the clearance of triglycerides; therefore, administration of bile acid sequestrants interrupts this feedback mechanism and may result in decreased clearance of triglycerides and hypertriglyceridemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19875558']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19875558'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied. <i></i></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>
<i>:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Elevated baseline fasting triglyceride concentrations (eg, ≥250 mg/dL) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774','lexi-content-ref-24239923']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774','lexi-content-ref-24239923'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Type III hyperlipoproteinemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24239923']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24239923'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F150841"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema, syncope</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Perianal skin irritation, skin irritation, skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperchloremic metabolic acidosis (Kamar 2015), hypertriglyceridemia, vitamin A deficiency, vitamin D deficiency (Heaton 1972), vitamin K deficiency (Vroonhof 2003), weight gain, weight loss</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distress, abdominal pain, anorexia, biliary colic, constipation, dental caries, diarrhea, diverticulitis of the gastrointestinal tract, duodenal ulcer with hemorrhage, dysphagia, eructation, flatulence, gallbladder calcification, gastric ulcer, gastrointestinal obstruction (Tonstand 1996), hiccups, nausea, pancreatitis, rectal pain, sour taste, staining of tooth, steatorrhea, tongue irritation, tooth enamel erosion, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Burnt odor to urine, diuresis, dysuria</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia, hemorrhage (Gross 1970)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal liver function</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness, drowsiness, fatigue, headache, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, back pain, myalgia, osteoporosis</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea, wheezing</p></div>
<div class="block coi drugH1Div" id="F150856"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to bile acid sequestering resins or any component of the formulation; complete biliary obstruction</p></div>
<div class="block war drugH1Div" id="F150838"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use caution in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Phenylalanine: Some products may contain phenylalanine.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperlipidemia: Secondary causes of hyperlipidemia should be ruled out prior to therapy.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878382"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Prolonged exposure to tooth enamel may result in discoloration or erosion; patients should be instructed to avoid sipping or slowly swallowing cholestyramine doses and to maintain good dental hygiene practices.</p></div>
<div class="block foc drugH1Div" id="F150849"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Packet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Prevalite: 4 g (1 ea, 42 ea, 60 ea) [contains aspartame; orange flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Questran: 4 g (1 ea, 60 ea) [contains fd&amp;c yellow #6 (sunset yellow), quinoline yellow (d&amp;c yellow #10); orange flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 4 g (1 ea, 60 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Powder, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Prevalite: 4 g/dose (231 g) [contains aspartame; orange flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Questran: 4 g/dose (378 g) [contains fd&amp;c yellow #6 (sunset yellow), quinoline yellow (d&amp;c yellow #10); orange flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Questran Light: 4 g/dose (210 g) [sugar free; contains aspartame, fd&amp;c red #40 (allura red ac dye), quinoline yellow (d&amp;c yellow #10); orange flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 4 g/dose (201.6 g, 210 g, 231 g, 239.4 g, 348.6 g, 368.76 g, 378 g)</p></div>
<div class="block geq drugH1Div" id="F150834"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F150858"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Pack</b> (Cholestyramine Light Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 g (per each): $3.35 - $4.43</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Pack</b> (Cholestyramine Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 g (per each): $3.35 - $4.43</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Pack</b> (Prevalite Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 g (per each): $5.11</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Pack</b> (Questran Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 g (per each): $7.11</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Powder</b> (Cholestyramine Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 g/dose (per gram): $0.23 - $1.59</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Powder</b> (Prevalite Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 g/dose (per gram): $0.59</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Powder</b> (Questran Light Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 g/dose (per gram): $0.89</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Powder</b> (Questran Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 g/dose (per gram): $0.49</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866319"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Packet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Olestyr: 4 g (4 g) [contains fd&amp;c yellow #6(sunset yellow)alumin lake, quinoline (d&amp;c yellow #10) aluminum lake, quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Olestyr Light: 4 g (4 g) [contains aspartame, fd&amp;c yellow #6 (sunset yellow), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 4 g (4 g, 30 ea)</p></div>
<div class="block admp drugH1Div" id="F52612412"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer as prepared suspension; not to be taken in dry form orally; suspension should not be sipped or held in mouth for prolonged periods (may cause tooth discoloration or enamel decay). Administration at mealtime is recommended. Administer other drugs including vitamins or mineral supplements at least 1 hour before or at least 4 to 6 hours after cholestyramine.</p>
<p style="text-indent:-2em;margin-left:2em;">Dyslipidemia: Administer as a single dose (preferably) with the evening meal; however, some patients may require divided doses; in pediatric patients, may use 2 to 3 divided doses and in adults up to 6 doses daily.</p>
<p style="text-indent:-2em;margin-left:2em;">Pruritus; cholestasis: Administer before breakfast (gall bladder has highest concentration of bile acids available for binding); for patients with an intact gall bladder, it has been suggested to administer the first dose 30 minutes before breakfast, the second dose 30 minutes after breakfast, and the final dose with lunch (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17519457']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17519457'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Enteral tube administration: One sachet (4 g) mixed in 100 mL of water (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-White.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-White.1'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F150853"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer prepared suspension orally. Not to be taken in dry form. Suspension should not be sipped or held in mouth for prolonged periods (may cause tooth discoloration or enamel decay). Administration at mealtime is recommended. Twice-daily dosing is recommended but may be administered in 1 to 6 doses daily. In general, administer other oral medications, including vitamins or mineral supplements, at least 1 hour before or 4 to 6 hours after cholestyramine; consult drug interactions database for additional information.</p></div>
<div class="block sts drugH1Div" id="F150865"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).</p></div>
<div class="block usep drugH1Div" id="F53566053"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Adjunct to diet in the management of primary hypercholesterolemia (FDA approved in adults); pruritus associated with elevated levels of bile acids associated with biliary obstruction (FDA approved in adults); has also been used to manage diarrhea associated with excess fecal bile acids; applied topically to treat diaper dermatitis and as a skin-protectant around enterostomy fistula sites.</p></div>
<div class="block cyt drugH1Div" id="F13299034"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F150843"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Amiodarone: Bile Acid Sequestrants may decrease the bioavailability of Amiodarone.  Management: Consider alternatives to this combination due to the risk of subtherapeutic amiodarone serum concentrations. If amiodarone is coadministered with colesevelam, administer amiodarone at least 4 hours before colesevelam.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cardiac Glycosides: Bile Acid Sequestrants may decrease the absorption of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chenodiol: Bile Acid Sequestrants may decrease the serum concentration of Chenodiol.  Management: Administration of chenodiol 5 hours or more after bile acid sequestrants may reduce the magnitude of this interaction.  Monitor for decreased therapeutic effects of chenodiol in patients receiving bile acid sequestrants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholic Acid: Bile Acid Sequestrants may decrease the absorption of Cholic Acid.  Management: Administer cholic acid at least 1 hour before or 4 to 6 hours after administration of any bile acid-binding products to minimize the potential for a significant interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Oral): Bile Acid Sequestrants may decrease the absorption of Corticosteroids (Oral). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferasirox: Bile Acid Sequestrants may decrease the serum concentration of Deferasirox.  Management: Avoid combination when possible; if the combination must be used, consider a 50% increase in initial deferasirox dose, with monitoring of serum ferritin concentrations and clinical responses to guide further dosing.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ethinyl Estradiol-Containing Products: Bile Acid Sequestrants may decrease the serum concentration of Ethinyl Estradiol-Containing Products.  Management: Administer ethinyl estradiol-containing products 4 hours prior to the administration of a bile acid sequestrant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ezetimibe: Bile Acid Sequestrants may decrease the absorption of Ezetimibe.  Management: Administer ezetimibe at least 2 hours before or 4 hours after any bile acid sequestrant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fibric Acid Derivatives: Bile Acid Sequestrants may decrease the absorption of Fibric Acid Derivatives.  Management: Separate doses by at least 2 hours to minimize this interaction; fenofibric acid labeling recommends administration one hour prior to or 4-6 hours after a bile acid sequestrant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluvastatin: Cholestyramine Resin may decrease the serum concentration of Fluvastatin.  Management: Separate the administration of fluvastatin and cholestyramine to maximize fluvastatin absorption. Administer fluvastatin 2 to 4 hours, or longer, after cholestyramine administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Bile Acid Sequestrants may decrease serum concentrations of the active metabolite(s) of Leflunomide.  Management: Unless using this combination to intentionally enhance leflunomide elimination, consider an alternative to the bile acid sequestrants when possible.  Separating drug administration is not likely to be effective at avoiding this interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lomitapide: Bile Acid Sequestrants may decrease the absorption of Lomitapide.  Management: Administer lomitapide at least 4 hours before or after administration of a bile acid sequestrant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: Bile Acid Sequestrants may decrease the absorption of Loop Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maralixibat: Bile Acid Sequestrants may decrease the serum concentration of Maralixibat.  Management: Bile acid sequestrants should be administered either at least 4 hours before, or 4 hours after, maralixibat.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: Bile Acid Sequestrants may decrease the absorption of Methotrexate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Fluoride (with ADE): Bile Acid Sequestrants may decrease the serum concentration of Multivitamins/Fluoride (with ADE).  Management: Avoid concomitant administration of multivitamins and bile acid sequestrants (eg, cholestyramine). Separate administration of these agents by several hours to minimize the risk of an interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): Bile Acid Sequestrants may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, bile acid sequestrants may impair the absorption of fat-soluble vitamins.  Management: Avoid concomitant administration of multivitamins and bile acid sequestrants (eg, cholestyramine). Separate administration of these agents by several hours to minimize the risk of an interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with AE, No Iron): Bile Acid Sequestrants may decrease the serum concentration of Multivitamins/Minerals (with AE, No Iron).  Management: Avoid concomitant administration of multivitamins and bile acid sequestrants (e.g., cholestyramine). Separate administration of these agents by several hours to minimize the risk of an interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mycophenolate: Cholestyramine Resin may decrease the serum concentration of Mycophenolate. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Niacin: Bile Acid Sequestrants may decrease the absorption of Niacin.  Management: Consider separating the administration times of niacin and bile acid sequestrants by a few hours in order to reduce the potential for decreased efficacy of these agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: Bile Acid Sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obeticholic Acid: Bile Acid Sequestrants may decrease the serum concentration of Obeticholic Acid.  Management: Administer obeticholic acid at least 4 hours before or at least 4 hours after the administration of bile acid sequestrants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Odevixibat: Bile Acid Sequestrants may decrease the serum concentration of Odevixibat.  Management: Bile acid sequestrants should be administered either at least 4 hours before, or 4 hours after, odevixibat.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">PHENobarbital: Cholestyramine Resin may decrease the serum concentration of PHENobarbital.  Management: Administer phenobarbital at least 1 hour before or 4 to 6 hours after administration of cholestyramine in order to minimize the risk for any significant interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pravastatin: Bile Acid Sequestrants may decrease the serum concentration of Pravastatin.  Management: Administer pravastatin at least 1 hour before or 4 hours after administration of bile-acid resins (eg, cholestyramine, colestipol, colesevelam) to minimize the risk for any significant interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propranolol: Bile Acid Sequestrants may decrease the serum concentration of Propranolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Raloxifene: Bile Acid Sequestrants may decrease the absorption of Raloxifene.  Management: Consider separating the doses of raloxifene and bile acid sequestrants by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rosiglitazone: Cholestyramine Resin may decrease the serum concentration of Rosiglitazone.  Management: Administer rosiglitazone at least 2 hours prior to cholestyramine in order to minimize the likelihood of an interaction, and monitor patients closely for evidence of reduced rosiglitazone effectiveness.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sincalide: Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide.  Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Spironolactone: Cholestyramine Resin may enhance the adverse/toxic effect of Spironolactone. Specifically, the risks of developing metabolic acidosis and hyperkalemia may be elevated with this combination. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Taurursodiol: Bile Acid Sequestrants may decrease the absorption of Taurursodiol. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teriflunomide: Bile Acid Sequestrants may decrease the serum concentration of Teriflunomide.  Management: Unless using this combination to intentionally enhance teriflunomide elimination, consider an alternative to the bile acid sequestrants when possible.  Separating drug administration is unlikely to be effective at avoiding the interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetracyclines: Bile Acid Sequestrants may decrease the absorption of Tetracyclines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: Bile Acid Sequestrants may decrease the absorption of Thiazide and Thiazide-Like Diuretics. The diuretic response is likewise decreased.  Management: Consider separating administraton of bile acid sequestrants and thiazide diuretics by at least 4 hours. Monitor for decreased therapeutic effects of thiazide diuretics if coadministered with a bile acid sequestrant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thyroid Products: Bile Acid Sequestrants may decrease the serum concentration of Thyroid Products.  Management: Administer oral thyroid products at least 4 hours prior to or one hour after bile acid sequestrants, or monitor for decreased serum concentrations and clinical effects of oral thyroid products during coadministration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ursodiol: Bile Acid Sequestrants may decrease the serum concentration of Ursodiol.  Management: Administer ursodiol 1 hour before or at least 4 to 5 hours after bile acid sequestrants to minimize the potential for any significant interaction. Monitor for decreased therapeutic effects of ursodiol in patients receiving bile acid sequestrants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valproic Acid and Derivatives: Cholestyramine Resin may decrease the serum concentration of Valproic Acid and Derivatives.  Management: Separate administration of valproic acid and cholestyramine by at least 3 hours whenever possible in order to minimize this interaction. The impact of concurrent cholestyramine on delayed- or extended-release valproic acid is uncertain.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin D Analogs: Bile Acid Sequestrants may decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs.  Management: Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (eg, cholestyramine). Separate administration of these agents by several hours to minimize the potential risk of interaction. Monitor plasma calcium concentrations.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Cholestyramine Resin may decrease the serum concentration of Vitamin K Antagonists.  Management: Separate the administration of vitamin K antagonists and cholestyramine by at least 3 to 4 hours. Monitor patients closely for reduced vitamin K antagonist effects (eg, decreased INR, thrombosis) when these agents are combined.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F150866"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Cholestyramine (especially high doses or long-term therapy) may decrease the absorption of folic acid, calcium, fat-soluble vitamins (vitamins A, D, E, and K), and iron. Management: Supplementation of folic acid, calcium, fat-soluble vitamins (vitamins A, D, E, and K), and iron may be necessary.</p></div>
<div class="block dic drugH1Div" id="F150860"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Supplementation of vitamins A, D, E, and K, folic acid, and iron may be required with high-dose, long-term therapy. Some products may contain phenylalanine.</p></div>
<div class="block rep_considerations drugH1Div" id="F54796220"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Cholestyramine is used off label to enhance leflunomide elimination. Use of the enhanced elimination procedure is recommended in all females of reproductive potential upon discontinuation of leflunomide. Pregnancy should be avoided until undetectable serum concentrations (&lt;0.02 mg/L) of leflunomide are verified (Brent 2001).</p></div>
<div class="block pri drugH1Div" id="F150859"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;margin-left:0em;">Lipid concentrations increase during pregnancy as required for normal fetal development. When increases are greater than expected, supervised dietary intervention should be initiated. Bile acid sequestrants are recommended when treatment is needed (Avis 2009; Jacobson 2015).</p>
<p style="text-indent:0em;margin-left:0em;margin-top:2em;">Cholestyramine is not absorbed systemically, but may interfere with maternal vitamin absorption; therefore, regular prenatal supplementation may not be adequate.</p></div>
<div class="block mopp drugH1Div" id="F53566010"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Pediatric patients: Fasting lipid profile (baseline, 4 to 6 weeks after initiation, and then every 6 to 12 months), growth, maturation, number of stools per day (NHLBI 2011); nutritional status for vitamin (eg, fat-soluble, folic acid) and nutrient deficiencies (eg, Ca, Fe) (Allard 1989; Parekh 2007).</p>
<p style="text-indent:-2em;margin-left:2em;">Adults: Fasting lipid profile before initiating treatment, 3 months after initiation (within 4 to 6 weeks if baseline fasting triglycerides of 250 to 299 mg/dL), and every 6 to 12 months thereafter (ACC/AHA [Stone 2013]).</p></div>
<div class="block pha drugH1Div" id="F150837"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Forms a nonabsorbable complex with bile acids in the intestine, releasing chloride ions in the process; inhibits enterohepatic reuptake of intestinal bile salts and thereby increases the fecal loss of bile salt-bound low density lipoprotein cholesterol</p></div>
<div class="block phk drugH1Div" id="F150855"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: Peak effect: 21 days </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: None </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Feces (as insoluble complex with bile acids)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F150861"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Cholestyramine | Questran</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Lestec | Nivelipol resina | Questran</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Questran lite</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Questran</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Questran light</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Quantalan</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Questran | Questran light | Resincolestiramina</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Cholestyramine | Xiao dan an</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Antilip | Colestepril | Colestiramina | Questran</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Holestan | Questran | Vasosan</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Colesthexal | Colestyr | Colestyramin | Colestyramin 1 A Pharma | Colestyramin hexal | Colestyramin klast | Lipocol | Quantalan | Quantalan Beragena | Questran zuckerfrei | Vasosan p | Vasosan s</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Colestiramina lam</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Colestiramina | Questran</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Colestyramin hexal | Colestyramin orifarm | Colestyramin ratiopharm | Quantalan | Questran | Questran light</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Cholestran | Questran | Resincolestiramina</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Resincolestiramina</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Cuemid | Questran</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Colestyramine Dci | Questran</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Cholemin | Cholestyramin kent | Cholestyramine | Cholestyramine cox | Cuemid | Questran</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Questran | Resincolestiramina | Vasosan p</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apt Cholestyramine | Pms cholestyramine | Questran | Resincolestiramina</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Cholestyramine supremex | Colestyramin hexal | Questran</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Questran</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Questran</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Cholless | Questran</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Choltran | Co diet</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Colestrol | Questran</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Questran</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Questran aventis | Questran bristol myers</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Bitran | Questran</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Questran</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Questran | Resincolestiramina</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Cholestyramin | Cholestyramine | Colestyr | Colestyramin ratiopharm | Holestan | Resincolestiramina | Vasosan</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Questran</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Cholestyramin | Colestyramin | Colestyramin hexal | Colestyramin ratiopharm | Holestan | Quantalan | Questran | Questran light | Vasosan</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Questran</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Glibofhen | Lhibre | Lipiramina | Nozacol | Questran</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Pms cholestyramine | Questran</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Colestyramin ratiopharm | Colestyramine gf | Questran | Questran-a</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Colestyramin orifarm | Quantalan | Questran | Questran light | Questran loc</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Questran</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Colestiramina</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Cholestyramin | Colestyramin hexal | Colestyramin ratiopharm | Quantalan | Questran | Questran light | Vasosan p | Vasosan s</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Cholestyramine | Cholestyramine light | Locholest | Prevalite | Questran | Questran light</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Quantalan | Questran</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">PMS-Cholestyramine | Questran Light</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Questran</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Questran</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Pms cholestyramine | Questran</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Kolestyramin Alternova | Questran | Questran loc</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Cholestyramine | Questran | Resincolestiramina</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Quantalan | Resincolestiramina | Sevit</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Questran</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Questran light | Resincolestiramina</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Pms cholestyramine | Questran</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Kolestran</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Choles | Cholestyramine | Questran | Questran light | Semide</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Cinecolex | Resincolestiramina</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Questran | Questran lite</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-2509356">
<a name="2509356"></a>Allard JP, Jeejeebhoy KN. Nutritional support and therapy in the short bowel syndrome. <i>Gastroenterol Clin North Am</i>. 1989;18(3):589-601.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/2509356/pubmed" id="2509356" target="_blank">2509356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26207323">
<a name="26207323"></a>Alswat KA. Role of cholestyramine in refractory hyperthyroidism: a case report and literature review. <i>Am J Case Rep</i>. 2015;16:486-490.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/26207323/pubmed" id="26207323" target="_blank">26207323</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30567262">
<a name="30567262"></a>Andrade Luz I, Pereira T, Catorze N. Thyroid storm: a case of haemodynamic failure promptly reversed by aggressive medical therapy with antithyroid agents and steroid pulse. <i>BMJ Case Rep</i>. 2018;11(1):e226669. doi:10.1136/bcr-2018-226669<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/30567262/pubmed" id="30567262" target="_blank">30567262</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Arava.2016">
<a name="Arava.2016"></a>Arava (leflunomide) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis; October 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24921636">
<a name="24921636"></a>Arnold MA, Swanson BJ, Crowder CD, et al. Colesevelam and colestipol: novel medication resins in the gastrointestinal tract. <i>Am J Surg Pathol</i>. 2014;38(11):1530-1537. doi:10.1097/PAS.0000000000000260<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/24921636/pubmed" id="24921636" target="_blank">24921636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19741526">
<a name="19741526"></a>Avis HJ, Hutten BA, Twickler MT, et al. Pregnancy in women suffering from familial hypercholesterolemia: a harmful period for both mother and newborn? <i>Curr Opin Lipidol.</i> 2009;20(6):484-490. doi: 10.1097/MOL.0b013e3283319127. Review.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/19741526/pubmed" id="19741526" target="_blank">19741526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16616026">
<a name="16616026"></a>Bays HE, Davidson M, Jones MR, Abby SL. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia. <i>Am J Cardiol</i>. 2006;97(8):1198-1205. doi:10.1016/j.amjcard.2005.11.039. Erratum in: <i>Am J Cardiol</i>. 2006;98(3):428.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/16616026/pubmed" id="16616026" target="_blank">16616026</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-717343">
<a name="717343"></a>Bernsten B, Zoger S. Hyperchloremic metabolic acidosis with cholestyramine therapy for biliary cholestasis. <i>Am J Dis Child</i>. 1978;132(12):1220. doi:10.1001/archpedi.1978.02120370072021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/717343/pubmed" id="717343" target="_blank">717343</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22075299">
<a name="22075299"></a>Borghede MK, Schlütter JM, Agnholt JS, Christensen LA, Gormsen LC, Dahlerup JF. Bile acid malabsorption investigated by selenium-75-homocholic acid taurine ((75)SeHCAT) scans: causes and treatment responses to cholestyramine in 298 patients with chronic watery diarrhoea. <i>Eur J Intern Med</i>. 2011;22(6):e137-140.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/22075299/pubmed" id="22075299" target="_blank">22075299</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11241434">
<a name="11241434"></a>Brent RL. Teratogen update: reproductive risks of leflunomide (Arava); a pyrimidine synthesis inhibitor: counseling women taking leflunomide before or during pregnancy and men taking leflunomide who are contemplating fathering a child. <i>Teratology</i>. 2001;63(2):106-112. doi:10.1002/1096-9926(200102)63:2&lt;106::AID-TERA1017&gt;3.0.CO;2-R<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/11241434/pubmed" id="11241434" target="_blank">11241434</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11837558">
<a name="11837558"></a>Btaiche IF and Khalidi N, "Parenteral Nutrition-Associated Liver Complications in Children," <i>Pharmacotherapy</i>, 2002, 22(2):188-211.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/11837558/pubmed" id="11837558" target="_blank">11837558</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Carney LN, Nepa A, Cohen SS, et al, “Parenteral and Enteral Nutrition Support: Determining the Best Way to Feed,” In: Corkins MR, Balint J, Bobo E, et al, eds, <i>The A.S.P.E.N Pediatric Nutrition Support Core Curriculum</i>, Silver Spring: MD: American Society of Parenteral and Enteral Nutrition, 2010, 433-47.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23148158">
<a name="23148158"></a>Carroll R, Matfin G. Endocrine and metabolic emergencies: thyroid storm. <i>Ther Adv Endocrinol Metab</i>. 2010;1(3):139-145. doi:10.1177/2042018810382481<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/23148158/pubmed" id="23148158" target="_blank">23148158</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20131283">
<a name="20131283"></a>Chambers CD, Johnson DL, Robinson LK, et al; Organization of Teratology Information Specialists Collaborative Research Group. Birth outcomes in women who have taken leflunomide during pregnancy. <i>Arthritis Rheum</i>. 2010;62(5):1494-1503. doi:10.1002/art.27358<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/20131283/pubmed" id="20131283" target="_blank">20131283</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18042954">
<a name="18042954"></a>Ching YA, Gura K, and Modi B, "Pediatric Intestinal Failure: Nutrition, Pharmacologic, and Surgical Approaches," <i>Nutr Clin Pract</i>, 2007, 22(6):653-63.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/18042954/pubmed" id="18042954" target="_blank">18042954</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Cholestyramine [prescribing information]. Maple Grove, MN: Upsher-Smith Laboratories, LLC; December 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17519457">
<a name="17519457"></a>Cies JJ and Giamalis JN, "Treatment of Cholestatic Pruritus in Children," <i>Am J Health Syst Pharm</i>, 2007, 64(11):1157-62.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/17519457/pubmed" id="17519457" target="_blank">17519457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3861176">
<a name="3861176"></a>Clouston WM, Lloyd HM. Cholestyramine induced hyperchloremic metabolic acidosis. <i>Aust N Z J Med</i>. 1985;15(2):271. doi:10.1111/j.1445-5994.1985.tb04032.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/3861176/pubmed" id="3861176" target="_blank">3861176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-640344">
<a name="640344"></a>Compston JE, Horton LW. Oral 25-hydroxyvitain D3 in treatment of osteomalacia associated with ileal resection and cholestyramine therapy. <i>Gastroenterology</i>. 1978;74(5 Pt 1):900-902.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/640344/pubmed" id="640344" target="_blank">640344</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Corkins.1">
<a name="Corkins.1"></a>Corkins MR, Balint J, Corkins KG, Bobo E, Plogsted S, Yaworski, JA, eds. <i>A.S.P.E.N. Pediatric Nutrition Support Handbook</i>. 2nd ed. Silver Spring, MD: American Society for Enteral and Parenteral Nutrition; 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Daniels.1">
<a name="Daniels.1"></a>Daniels SR, personal communication, May 2002.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27482192">
<a name="27482192"></a>Desai M, Reiprich A, Khov N, Yang Z, Mathew A, Levenick J. Crystal-associated colitis with ulceration leading to hematochezia and abdominal pain. <i>Case Rep Gastroenterol</i>. 2016;10(2):332-337. doi:10.1159/000446575<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/27482192/pubmed" id="27482192" target="_blank">27482192</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6597713">
<a name="6597713"></a>Eaves ER, Korman MG. Cholestyramine induced hyperchloremic metabolic acidosis. <i>Aust N Z J Med</i>. 1984;14(5):670-672. doi:10.1111/j.1445-5994.1984.tb05023.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/6597713/pubmed" id="6597713" target="_blank">6597713</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30926241">
<a name="30926241"></a>European Association for the Study of the Liver. EASL clinical practice guidelines: drug-induced liver injury. <i>J Hepatol</i>. 2019;70(6):1222-1261. doi:10.1016/j.jhep.2019.02.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/30926241/pubmed" id="30926241" target="_blank">30926241</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4746523">
<a name="4746523"></a>Faergeman O. Effects and side-effects of treatment of hypercholesterolemia with cholestyramine and neomycin. <i>Acta Med Scand</i>. 1973;194(3):165-167. doi:10.1111/j.0954-6820.1973.tb19425.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/4746523/pubmed" id="4746523" target="_blank">4746523</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23166211">
<a name="23166211"></a>Fihn SD, Gardin JM, Abrams J, et al, “2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,” <i>Circulation</i>, 2012, 126(25):3097-137.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/23166211/pubmed" id="23166211" target="_blank">23166211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gal.2007">
<a name="Gal.2007"></a>Gal P, Reed M. Medications. In: Kliegman RM, Behrman RE, Jenson HB, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 18th ed. Philadelphia, PA: Saunders Elsevier; 2007: 2955-2999.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5410402">
<a name="5410402"></a>Gross L, Brotman M. Hypoprothrombinemia and hemorrhage associated with cholestyramine therapy. <i>Ann Intern Med</i>. 1970;72(1):95-96. doi:10.7326/0003-4819-72-1-95.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/5410402/pubmed" id="5410402" target="_blank">5410402</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30586774">
<a name="30586774"></a>Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Circulation</i>. 2019;139(25):e1082-e1143. doi:10.1161/CIR.0000000000000625. Erratum in: <i>Circulation</i>. 2019;139(25):e1182-e1186.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/30586774/pubmed" id="30586774" target="_blank">30586774</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5020877">
<a name="5020877"></a>Heaton KW, Lever JV, Barnard D. Osteomalacia associated with cholestyramine therapy for postileectomy diarrhea. <i>Gastroenterology</i>. 1972;62(4):642-646.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/5020877/pubmed" id="5020877" target="_blank">5020877</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4894463">
<a name="4894463"></a>Hofmann AF, Poley JR. Cholestyramine treatment of diarrhea associated with ileal resection. <i>N Engl J Med</i>. 1969;281(8):397-402.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/4894463/pubmed" id="4894463" target="_blank">4894463</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22413872">
<a name="22413872"></a>Imam MH, Gossard AA, and Sinakos E, "Pathogenesis and Management of Pruritus in Cholestatic Liver Disease," <i>J Gastroenterol Hepatol</i>, 2012, 27(7):1150-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/22413872/pubmed" id="22413872" target="_blank">22413872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17368279">
<a name="17368279"></a>Jacobson TA, Armani A, McKenney JM, Guyton JR. Safety considerations with gastrointestinally active lipid-lowering drugs. <i>Am J Cardiol</i>. 2007;99(6A):47C-55C. doi:10.1016/j.amjcard.2006.11.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/17368279/pubmed" id="17368279" target="_blank">17368279</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26699442">
<a name="26699442"></a>Jacobson TA, Maki KC, Orringer CE, et al; NLA Expert Panel. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 2. <i>J Clin Lipidol.</i> 2015;9(6 Suppl):S1-122.e1. doi: 10.1016/j.jacl.2015.09.002.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/26699442/pubmed" id="26699442" target="_blank">26699442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28437620">
<a name="28437620"></a>Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. <i>Endocr Pract</i>. 2017;23(suppl 2):1-87. doi: 10.4158/EP171764.APPGL.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/28437620/pubmed" id="28437620" target="_blank">28437620</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26425378">
<a name="26425378"></a>Kamar FB, McQuillan RF. Hyperchloremic metabolic acidosis due to cholestyramine: a case report and literature review. <i>Case Rep Nephrol</i>. 2015;2015:309791. doi:10.1155/2015/309791<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/26425378/pubmed" id="26425378" target="_blank">26425378</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4817847">
<a name="4817847"></a>Kleinman PK. Letter: Cholestyramine and metabolic acidosis. <i>N Engl J Med</i>. 1974;290(15):861.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/4817847/pubmed" id="4817847" target="_blank">4817847</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kliegman.1">
<a name="Kliegman.1"></a>Kliegman RM and St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Philadelphia, PA: Saunders Elsevier; 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15752303">
<a name="15752303"></a>Knab J, Goos M, Dissemond J. Successful treatment of a leg ulcer occurring in a rheumatoid arthritis patient under leflunomide therapy. <i>J Eur Acad Dermatol Venereol</i>. 2005;19(2):243-246. doi:10.1111/j.1468-3083.2005.01118.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/15752303/pubmed" id="15752303" target="_blank">15752303</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22284265">
<a name="22284265"></a>Kulaksizoglu M, Gonen MS, Kebapcilar L, et al. Multiorgan dysfunction accompanied with metimazole and thyroid storm. <i>Transfus Apher Sci</i>. 2012;46(2):149-152. doi:10.1016/j.transci.2012.01.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/22284265/pubmed" id="22284265" target="_blank">22284265</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26446104">
<a name="26446104"></a>Laub M, Fraser R, Kurche J, Lara A, Kiser TH, Reynolds PM. Use of a cholestyramine washout in a patient with septic shock on leflunomide therapy: a case report and review of the literature. <i>J Intensive Care Med</i>. 2016;31(6):412-414. doi:10.1177/0885066615610108<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/26446104/pubmed" id="26446104" target="_blank">26446104</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30070375">
<a name="30070375"></a>Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases. <i>Hepatology</i>. 2019;69(1):394-419. doi: 10.1002/hep.30145.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/30070375/pubmed" id="30070375" target="_blank">30070375</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19554543">
<a name="19554543"></a>Lindor KD, Gershwin ME, Poupon R, et al, "Primary Biliary Cirrhosis," <i>Hepatology</i>, 2009, 50(1):291-308.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/19554543/pubmed" id="19554543" target="_blank">19554543</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-850604">
<a name="850604"></a>Lloyd-Still JD. Cholestyramine therapy and intestinal obstruction in infants. <i>Pediatrics</i>. 1977;59(4):626-627.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/850604/pubmed" id="850604" target="_blank">850604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6361299">
<a name="6361299"></a>The Lipid Research Clinics Coronary Primary Prevention Trial (LRCCPPT) results. I. Reduction in incidence of coronary heart disease. <i>JAMA</i>. 1984;251(3):351-364. doi:10.1001/jama.1984.03340270029025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/6361299/pubmed" id="6361299" target="_blank">6361299</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17377073">
<a name="17377073"></a>McCrindle BW, Urbina EM, Dennison BA, et al, "Drug Therapy of High-Risk Lipid Abnormalities in Children and Adolescents: A Scientific Statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, With the Council on Cardiovascular Nursing," <i>Circulation</i>, 2007, 115(14):1948-67.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/17377073/pubmed" id="17377073" target="_blank">17377073</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16971976">
<a name="16971976"></a>McPherson R, Frohlich J, Fodor G, et al, “Canadian Cardiovascular Society Position Statement--Recommendations for the Diagnosis and Treatment of Dyslipidemia and Prevention of Cardiovascular Disease,” [published correction appears in <i>Can J Cardiol</i>. 2006, 22(12):1077]. <i>Can J Cardiol</i>. 2006;22(11):913-927.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/16971976/pubmed" id="16971976" target="_blank">16971976</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8784067">
<a name="8784067"></a>Mercado M, Mendoza-Zubieta V, Bautista-Osorio R, Espinoza-de los Monteros AL. Treatment of hyperthyroidism with a combination of methimazole and cholestyramine. <i>J Clin Endocrinol Metab</i>. 1996;81(9):3191-3193. doi:10.1210/jcem.81.9.8784067<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/8784067/pubmed" id="8784067" target="_blank">8784067</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6767374">
<a name="6767374"></a>Merten DF, Grossman H. Intestinal obstruction associated with cholestyramine therapy. <i>AJR Am J Roentgenol</i>. 1980;134(4):827-828. doi:10.2214/ajr.134.4.827<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/6767374/pubmed" id="6767374" target="_blank">6767374</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  National Heart, Lung, and Blood Institute. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents. Clinical Practice Guidelines, 2011, National Institutes of Health. Available at <a href="http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf%20" target="_blank">http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf </a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.2008">
<a name="NICE.2008"></a>National Institute for Health and Care Excellence (2008) Clinical guidelines and evidence review for familial hypercholesterolaemia: the identification and management of adults and children with familial hypercholesterolaemia. London: NICE. (Clinical Guideline 71). Available at: http://www.nice.org.uk/CG71.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17127140">
<a name="17127140"></a>Nayak B, Burman K. Thyrotoxicosis and thyroid storm. <i>Endocrinol Metab Clin North Am</i>. 2006;35(4):663-686, vii. doi:10.1016/j.ecl.2006.09.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/17127140/pubmed" id="17127140" target="_blank">17127140</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17298760">
<a name="17298760"></a>Parekh NR, Steiger E. Short bowel syndrome. <i>Curr Treat Options Gastroenterol</i>. 2007;10(1):10-23.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/17298760/pubmed" id="17298760" target="_blank">17298760</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Preckshot.1">
<a name="Preckshot.1"></a>Preckshot J, et al, "Cholestyramine 6.5% Ointment," <i>Int J Pharm Compound</i>, 2001, 5(1)42.</div>
</li>
<li>
<div class="reference">
                  Prevalite (cholestyramine) [prescribing information]. Maple Grove, MN: Upsher-Smith Laboratories, LLC; June 2020.</div>
</li>
<li>
<div class="reference">
                  Questran Powder, Questran Light (cholestyramine) [prescribing information]. Chestnut Ridge, NY: Par Pharmaceuticals; April 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8879322">
<a name="8879322"></a>Robertson KE, Mueller BA. Uremic pruritus. <i>Am J Health Syst Pharm.</i> 1996;53(18):2159-2170; quiz 2215-2216. doi:10.1093/ajhp/53.18.2159<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/8879322/pubmed" id="8879322" target="_blank">8879322</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ross.1">
<a name="Ross.1"></a>Ross DS. Thyroid storm. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 12, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27521067">
<a name="27521067"></a>Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. <i>Thyroid</i>. 2016;26(10):1343-1421. doi:10.1089/thy.2016.0229<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/27521067/pubmed" id="27521067" target="_blank">27521067</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7756215">
<a name="7756215"></a>Sadler LC, Lane M, North R. Severe fetal intracranial haemorrhage during treatment with cholestyramine for intrahepatic cholestasis of pregnancy. <i>Br J Obstet Gynaecol</i>. 1995;102(2):169-170. doi:10.1111/j.1471-0528.1995.tb09077.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/7756215/pubmed" id="7756215" target="_blank">7756215</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32010878">
<a name="32010878"></a>Sadowski DC, Camilleri M, Chey WD, et al. Canadian Association of Gastroenterology clinical practice guideline on the management of bile acid diarrhea. <i>J Can Assoc Gastroenterol.</i> 2020;3(1):e10-e27. doi:10.1093/jcag/gwz038<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/32010878/pubmed" id="32010878" target="_blank">32010878</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1634640">
<a name="1634640"></a>Scheel PJ Jr, Whelton A, Rossiter K, Watson A. Cholestyramine-induced hyperchloremic metabolic acidosis. <i>J Clin Pharmacol</i>. 1992;32(6):536-538. doi:10.1177/009127009203200608<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/1634640/pubmed" id="1634640" target="_blank">1634640</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3948073">
<a name="3948073"></a>Shojania AM, Grewar D. Hypoprothrombinemic hemorrhage due to cholestyramine therapy. <i>CMAJ</i>. 1986;134(6):609-610.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/3948073/pubmed" id="3948073" target="_blank">3948073</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28487440">
<a name="28487440"></a>Sjöberg BG, Straniero S, Angelin B, Rudling M. Cholestyramine treatment of healthy humans rapidly induces transient hypertriglyceridemia when treatment is initiated. <i>Am J Physiol Endocrinol Metab</i>. 2017;313(2):E167-E174. doi:10.1152/ajpendo.00416.2016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/28487440/pubmed" id="28487440" target="_blank">28487440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8435884">
<a name="8435884"></a>Solomon BL, Wartofsky L, Burman KD. Adjunctive cholestyramine therapy for thyrotoxicosis. <i>Clin Endocrinol (Oxf).</i> 1993;38(1):39-43. doi:10.1111/j.1365-2265.1993.tb00970.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/8435884/pubmed" id="8435884" target="_blank">8435884</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8757557">
<a name="8757557"></a>Sprecher DL and Daniels SR, “Rational Approach to Pharmacologic Reduction of Cholesterol Levels in Children,” <i>J Pediatr</i>, 1996, 129(1):4-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/8757557/pubmed" id="8757557" target="_blank">8757557</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19875558">
<a name="19875558"></a>Staels B, Fonseca VA. Bile acids and metabolic regulation: mechanisms and clinical responses to bile acid sequestration. <i>Diabetes Care</i>. 2009;32 Suppl 2(suppl 2):S237-S245. doi:10.2337/dc09-S355<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/19875558/pubmed" id="19875558" target="_blank">19875558</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26633044">
<a name="26633044"></a>Stine JG, Lewis JH. Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review. <i>Expert Rev Gastroenterol Hepatol</i>. 2016;10(4):517-536. doi:10.1586/17474124.2016.1127756<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/26633044/pubmed" id="26633044" target="_blank">26633044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24239923">
<a name="24239923"></a>Stone NJ, Robinson JG, Lichtenstein AH, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>J Am Coll Cardiol</i>. 2014;63(25 Pt B):2889-2934. doi:10.1016/j.jacc.2013.11.002. Erratum in: <i>J Am Coll Cardiol</i>. 2014;63(25 Pt B):3024-3025. Erratum in: <i>J Am Coll Cardiol</i>. 2015;66(24):2812.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/24239923/pubmed" id="24239923" target="_blank">24239923</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  "Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)," May 2001. Available at <a href="http://www.nhlbi.nih.gov/guidelines/cholesterol" target="_blank">http://www.nhlbi.nih.gov/guidelines/cholesterol</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8757561">
<a name="8757561"></a>Tonstad S, Knudtzon J, Sivertsen M, Refsum H, Ose L. Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia. <i>J Pediatr</i>. 1996;129(1):42-49. doi:10.1016/s0022-3476(96)70188-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/8757561/pubmed" id="8757561" target="_blank">8757561</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15853819">
<a name="15853819"></a>Tsai WC, Pei D, Wang TF, et al. The effect of combination therapy with propylthiouracil and cholestyramine in the treatment of Graves' hyperthyroidism. <i>Clin Endocrinol (Oxf)</i>. 2005;62(5):521-524. doi:10.1111/j.1365-2265.2005.02249.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/15853819/pubmed" id="15853819" target="_blank">15853819</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-13781611">
<a name="13781611"></a>Visintine Re, Michaels GD, Fukayama G, Conklin J, Kinsell LW. Xanthomatous biliary cirrhosis treated with cholestyramine. A bile-acid-adsorbing resin. <i>Lancet</i>. 1961;2(7198):341-343. doi:10.1016/s0140-6736(61)90634-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/13781611/pubmed" id="13781611" target="_blank">13781611</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12688565">
<a name="12688565"></a>Vroonhof K, van Rijn HJ, van Hattum J. Vitamin K deficiency and bleeding after long-term use of cholestyramine. <i>Neth J Med</i>. 2003;61(1):19-21.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/12688565/pubmed" id="12688565" target="_blank">12688565</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21180614">
<a name="21180614"></a>Walters JR, Pattni SS. Managing bile acid diarrhoea. <i>Therap Adv Gastroenterol</i>. 2010;3(6):349-357.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/21180614/pubmed" id="21180614" target="_blank">21180614</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1168607">
<a name="1168607"></a>West RJ, Lloyd JK. The effect of cholestyramine on intestinal absorption. <i>Gut</i>. 1975;16(2):93-98. doi:10.1136/gut.16.2.93.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/1168607/pubmed" id="1168607" target="_blank">1168607</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17298762">
<a name="17298762"></a>Westergaard H, “Bile Acid Malabsorption,” <i>Curr Treat Options Gastroenterol</i>, 2007, 10(1):28-33.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/17298762/pubmed" id="17298762" target="_blank">17298762</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-White.1">
<a name="White.1"></a>White R, Bradnam V; British Pharmaceutical Nutrition Group. <i> Handbook of Drug Administration via Enteral Feeding Tubes</i>. 3rd ed. London, England: Pharmaceutical Press; 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-White.2">
<a name="White.2"></a>White CM, Kalus JS, Caron MF, et al, "Cholestyramine Ointment Used on an Infant for Severe Buttocks Rash Resistant to Standard Therapeutic Modalities," <i>J Pharm Technol</i>, 2003, 19:11-3.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24602022">
<a name="24602022"></a>Wilcox C, Turner J, Green J. Systematic review: the management of chronic diarrhoea due to bile acid malabsorption. <i>Aliment Pharmacol Ther</i>. 2014;39(9):923-939.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/24602022/pubmed" id="24602022" target="_blank">24602022</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Williams.1">
<a name="Williams.1"></a>Williams KD and Williams L, "Diaper Rash Relief, Common Sense Remedies and Treatment," <i>Int J Pharm Compound</i>, 2011, 15(6):464-9.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22319420">
<a name="22319420"></a>Wise DM. Suppressed wound healing in a patient with rheumatoid arthritis taking leflunomide (arava). <i>Perm J</i>. 2011;15(4):70-74. doi:10.7812/tpp/11-044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/22319420/pubmed" id="22319420" target="_blank">22319420</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19955995">
<a name="19955995"></a>Wong SP, Chu CM, Kan CH, Tsui HS, Ng WL. Successful treatment of leflunomide-induced acute pneumonitis with cholestyramine wash-out therapy. <i>J Clin Rheumatol</i>. 2009;15(8):389-392. doi:10.1097/RHU.0b013e3181c3f87e<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/19955995/pubmed" id="19955995" target="_blank">19955995</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36031461">
<a name="36031461"></a>Writing Committee; Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: A report of the American College of Cardiology Solution Set Oversight Committee. <i>J Am Coll Cardiol</i>. 2022;80(14):1366-1418. doi:10.1016/j.jacc.2022.07.006 Erratum in: <i>J Am Coll Cardiol</i>. 2023;81(1):104.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cholestyramine-pediatric-drug-information/abstract-text/36031461/pubmed" id="36031461" target="_blank">36031461</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13152 Version 370.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
